ctDNA- and cfDNA-based liquid biopsy in bladder cancer and urothelial carcinoma: bibliometric mapping and cross-database coverage analysis, 2008-2025 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Analysis of Liquid Biopsy Utilizing ctDNA and cfDNA in Bladder Cancer and Urothelial Carcinoma: A Bibliometric Review and Database Coverage Assessment from 2008 to 2025

  • By

  • Junhua Li

  • Chenhao Tang

  • Longfei Yang

  • Chen Song

  • Huixian Pan

  • September 14, 2026

Share

  • 1

    The study analyzes the growth and coverage of literature on ctDNA and cfDNA in bladder cancer from 2008 to 2025.

  • 2

    A total of 1,903 records were found in WoSCC, 3,201 in Scopus, and 230 in PubMed/MEDLINE, indicating varied database coverage.

  • 3

    The main set of 494 records accumulated 17,031 citations, with a peak annual output of 82 records in 2025.

  • 4

    The research highlights a shift from early methylation studies to ctDNA-based evaluations for molecular residual disease.

  • 5

    Bibliometric prominence reflects research activity rather than diagnostic accuracy or treatment benefit in bladder cancer.

Original Source(s)

ctDNA- and cfDNA-based liquid biopsy in bladder cancer and urothelial carcinoma: bibliometric mapping and cross-database coverage analysis, 2008-2025

  • by Junhua Li, Chenhao Tang, Longfei Yang, Chen Song, Huixian Pan

  • September 14, 2026

Related Content

The Effectiveness of Digital Intervention on Psychological Resilience in Postoperative Breast Cancer Patients During Chemotherapy Intervals: Quasi-Experimental Study

Retraction Note: Lycorine inhibits angiogenesis by docking to PDGFRα

Cost-Effectiveness of Smoking Cessation Interventions Integrated Into Lung Cancer Screening